189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers
Nechiporchik N, Lieb K, Marquette L, Polin L, Peters G, Chen A, Ethier S, LoRusso P, Burger A. 189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers. European Journal Of Cancer Supplements 2010, 8: 64. DOI: 10.1016/s1359-6349(10)71894-2.Peer-Reviewed Original ResearchTriple-negative breast cancerNegative breast cancerPolymerase inhibitor ABT-888Preclinical activityBreast cancerABT-888IrinotecanCancer